TRIUMPH-1 Results: Retatrutide Achieves 30% Weight Loss in Pivotal Phase 3 Trial
Lilly's triple agonist produces 85-pound average weight loss over two years, rivaling bariatric surgery outcomes
Eli Lilly's retatrutide produced an average weight loss of 70.3 pounds (28.3%) over 80 weeks in the TRIUMPH-1 Phase 3 trial, with participants who continued to 104 weeks losing up to 85 pounds (30.3%). These results, announced May 21, 2026, represent the highest weight reduction ever recorded in a pivotal obesity trial and position retatrutide as a potential pharmaceutical alternative to bariatric surgery. Nearly half (45.3%) of participants on the 12 mg dose achieved at least 30% weight loss, a threshold historically associated with surgical intervention.
What Did TRIUMPH-1 Find?
TRIUMPH-1 (NCT05929066) enrolled 2,339 adults with obesity or overweight plus at least one weight-related comorbidity, but without diabetes. Participants were randomized 1:1:1:1 to receive retatrutide 4 mg, 9 mg, 12 mg, or placebo via once-weekly injection over 80 weeks.
All three retatrutide doses met the primary and key secondary endpoints.
The trial's lead investigator, Dr. Ania Jastreboff of the Yale Obesity Research Center, described the results: "It was impressive to see that every dose of retatrutide resulted in clinically meaningful weight reduction for nearly all participants, and people with severe obesity on the highest dose lost on average 30% of their body weight over two years."
Weight Loss Results by Dose
From an average starting weight of 248.5 pounds (BMI 40.0), participants achieved the following at 80 weeks:
| Dose | Weight Loss (lbs) | Weight Loss (%) | ≥25% Loss | ≥30% Loss |
|---|---|---|---|---|
| 4 mg | 47.2 lbs | 19.0% | 27.8% | 15.3% |
| 9 mg | 64.4 lbs | 25.9% | 52.9% | 37.9% |
| 12 mg | 70.3 lbs | 28.3% | 62.5% | 45.3% |
| Placebo | 5.5 lbs | 2.2% | 2.2% | 0.5% |
The 4 mg dose requires only a single escalation step (starting at 2 mg), making it a potentially more tolerable entry point for patients concerned about side effects. Lilly highlighted this dose as evidence of a "patient-centric approach to obesity."
At 12 mg, 65.3% of participants achieved a BMI under 30, falling below the clinical threshold for obesity. Among those who started with class 3 obesity (BMI ≥40), 37.5% dropped below BMI 30 by week 80.
Extended Results at 104 Weeks
A pre-specified extension enrolled 532 participants with baseline BMI ≥35 who completed the main trial without dose reduction. These individuals continued for an additional 24 weeks, escalating to their maximum tolerated dose (9 mg or 12 mg).
Results at 104 weeks from a starting weight of 268.3 pounds:
| Original Dose → MTD | Weight Loss (lbs) | Weight Loss (%) |
|---|---|---|
| 4 mg → MTD | 73.3 lbs | 27.9% |
| 9 mg → MTD | 80.7 lbs | 29.5% |
| 12 mg → MTD | 85.0 lbs | 30.3% |
| Placebo → MTD | 49.9 lbs | 19.2% |
Weight loss continued beyond 80 weeks rather than plateauing, which suggests participants had not yet reached equilibrium. The placebo-to-retatrutide crossover group lost 49.9 pounds (19.2%) in just 24 weeks of treatment.
Cardiometabolic Improvements
Beyond weight loss, retatrutide produced significant improvements in cardiovascular risk markers at 80 weeks on the 12 mg dose:
- Waist circumference: Reduced by 9.5 inches (from 46.6 inches baseline)
- Non-HDL cholesterol: Significant reduction
- Triglycerides: Significant reduction
- Systolic blood pressure: Significant reduction
- hsCRP (inflammation marker): Significant reduction
Lilly did not release exact values for lipid and blood pressure changes in the initial press release. Full data will be presented at the 86th American Diabetes Association Scientific Sessions.
Safety and Side Effects
The adverse event profile matched expectations for incretin-based therapies. Gastrointestinal symptoms were most common:
| Side Effect | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
| Nausea | 28.6% | 38.4% | 42.4% | 14.8% |
| Diarrhea | 25.2% | 34.1% | 32.0% | 13.5% |
| Constipation | 23.8% | 25.9% | 26.1% | 10.9% |
| Vomiting | 10.6% | 22.8% | 25.3% | 4.8% |
Dysesthesia (tingling, numbness, or altered skin sensations) occurred more frequently with retatrutide than with other incretin drugs: 5.1% at 4 mg, 12.3% at 9 mg, and 12.5% at 12 mg, compared to 0.9% with placebo. Lilly reported these events were generally mild to moderate, with most resolving during treatment. This signal is likely related to glucagon receptor activation.
Urinary tract infections were also elevated: 7.5-8.8% across retatrutide doses versus 5.3% with placebo.
Discontinuation rates due to adverse events were 4.1% (4 mg), 6.9% (9 mg), and 11.3% (12 mg), compared to 4.9% with placebo. The lower-dose arm actually had fewer dropouts than placebo.
How Does This Compare to Other Weight Loss Drugs?
Retatrutide's results exceed those of any FDA-approved anti-obesity medication:
| Drug | Mechanism | Max Weight Loss | Trial Duration |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | ~15% | 68 weeks |
| Tirzepatide (Zepbound) | GLP-1 + GIP | ~21% | 72 weeks |
| Retatrutide | GLP-1 + GIP + Glucagon | 28.3% (30.3% extended) | 80-104 weeks |
The incremental benefit comes from glucagon receptor activation, which increases resting energy expenditure, promotes liver fat oxidation, and stimulates thermogenesis. Single- and dual-agonist drugs work primarily through appetite suppression; retatrutide adds a metabolic boost that burns additional calories even at rest.
Bariatric surgery typically produces 25-35% weight loss depending on procedure type. Retatrutide's 30% result at 104 weeks puts it squarely in surgical territory, without the invasiveness, recovery time, or irreversibility of surgery.
What Comes Next for Retatrutide?
TRIUMPH-1 is the first pivotal trial in a program of four registrational studies. Upcoming readouts include:
- TRIUMPH-2: Adults with obesity/overweight and type 2 diabetes
- TRIUMPH-3: Adults with obesity and established cardiovascular disease
- Knee osteoarthritis and sleep apnea basket trials: Nested within TRIUMPH-1 (data to be released separately)
Full TRIUMPH-1 results will be presented at the American Diabetes Association Scientific Sessions in June 2026, with peer-reviewed publication to follow.
Based on the trial completion timeline, Eli Lilly is expected to submit a New Drug Application in late 2026 or early 2027. Under standard FDA review (10-12 months), approval could come in late 2027, with commercial launch likely in early 2028.
Retatrutide is not yet approved anywhere in the world. It remains available only to participants in Lilly's clinical trials.
Key Takeaways
- TRIUMPH-1 showed 28.3% weight loss at 80 weeks on retatrutide 12 mg, rising to 30.3% at 104 weeks in an extension cohort
- The 4 mg dose produced 19% weight loss with only one dose escalation step and fewer dropouts than placebo
- 45.3% of participants on the highest dose lost at least 30% of body weight, a level historically achieved only with bariatric surgery
- Gastrointestinal side effects were common but manageable; dysesthesia occurred in 12-13% of patients at higher doses
- FDA submission expected late 2026, with potential approval in late 2027
Frequently Asked Questions
How much weight can you lose on retatrutide?
In the TRIUMPH-1 trial, participants on the 12 mg dose lost an average of 70.3 pounds (28.3%) over 80 weeks. Those who continued to 104 weeks lost up to 85 pounds (30.3%). The 4 mg dose produced 47.2 pounds (19%) of weight loss with fewer side effects.
Is retatrutide better than tirzepatide for weight loss?
Based on separate trial data, retatrutide appears to produce greater weight loss. Tirzepatide (Zepbound) achieved approximately 21% weight loss at 72 weeks, while retatrutide achieved 28.3% at 80 weeks. A direct head-to-head comparison trial is underway, with results expected in December 2026.
When will retatrutide be available?
Retatrutide is not yet FDA approved. Eli Lilly is expected to submit for approval in late 2026 or early 2027, with a potential FDA decision in late 2027. Commercial availability would likely follow in early 2028.
What are the side effects of retatrutide?
The most common side effects are gastrointestinal: nausea (42%), diarrhea (32%), constipation (26%), and vomiting (25%) at the 12 mg dose. Dysesthesia (tingling or numbness) occurred in about 12% of patients at higher doses. Most side effects were mild to moderate and decreased over time.
How is retatrutide different from semaglutide?
Semaglutide activates only GLP-1 receptors. Retatrutide activates three receptors: GLP-1, GIP, and glucagon. The glucagon component increases energy expenditure, meaning your body burns more calories at rest. This may explain why retatrutide produces nearly twice the weight loss of semaglutide.
Conclusion
TRIUMPH-1 establishes retatrutide as the most effective anti-obesity drug ever tested in a Phase 3 trial. With 30% weight loss matching bariatric surgery outcomes and a tolerable side effect profile at lower doses, retatrutide could reshape treatment algorithms for obesity when it reaches the market.
The question now shifts from efficacy to regulatory strategy. Can Lilly secure FDA approval efficiently, and can it manufacture enough supply to meet demand? If tirzepatide's launch is any guide, the bigger challenge may be keeping up with patient interest rather than proving the drug works.
Additional TRIUMPH trials reporting throughout 2026 will fill in the picture for patients with diabetes, cardiovascular disease, and other comorbidities. For now, the 30% weight loss figure sets a new benchmark that competitors will need to match.
This article is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational drug not approved for any indication. Consult a healthcare provider before considering any weight loss treatment.
Sources
Written by
Peptide Portal Research
Editorial Team
Our research team combines expertise in biochemistry, pharmacology, and clinical research to deliver evidence-based content on peptide science.
Stay Updated
Get peptide research updates
Join 2,500+ researchers receiving our weekly digest of the latest peptide science and vendor insights.
No spam. Unsubscribe anytime.
Last updated May 21, 2026